Regeneron breaks into neurology with FDA nod in crowded myasthenia gravis
The FDA has approved Livsayis (cemdisiran), Regeneron's siRNA drug licensed from Alnylam, for adults with generalized myasthenia gravis (gMG). This marks Regeneron's first foray into neurology and its first small interfering RNA approval, despite entering an increasingly competitive gMG market. Livsayis is notable for being the first siRNA therapy for gMG to silence the C5 gene in the liver and for its unique subcutaneous administration four times a year, though challenges remain regarding healthcare provider administration and potential self-administration expansion for market uptake.
Vertex Pharmaceuticals director Bhatia disposes of shares worth $148,470
Sangeeta N. Bhatia, a director at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently sold 271 shares of common stock for a total of $148,470 at a price of $547.86 per share. This transaction was conducted under a Rule 10b5-1 trading plan established in August 2026. The sale occurred as Vertex shares are trading near their 52-week high, and the stock is considered overvalued according to InvestingPro analysis, despite recent positive third-quarter results and upward adjustments in price targets by several analyst firms.
Form 4 Vertex Pharmaceuticals Inc: Sangeeta N. Bhatia (Director) For: 16 November
This article reports on a Form 4 filing for Vertex Pharmaceuticals Inc, indicating that Director Sangeeta N. Bhatia had a transaction on November 16th. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by its insiders. The article does not provide specific details about the nature of the transaction.
Genomics, Vertex extend drug discovery alliance in $220m deal
Vertex Pharmaceuticals and Genomics have extended their drug discovery partnership for another four years, in a deal potentially worth over $220 million. The collaboration, which began in 2018, will continue to focus on applying human genetics to identify and validate new drug targets and biomarkers for precision medicines. This extension highlights the success of their nearly decade-long joint effort in integrating human genetic variation into research and development.
AbCellera Biologics (ABCL) Stock Looks Reasonable Following Its 221% Run
AbCellera Biologics (ABCL) has seen its share price surge by 221.3% year-to-date, prompting an evaluation of its current valuation against its book value. The stock trades at approximately 3.4x book value, aligning closely with the Life Sciences industry average, suggesting the market has priced in recent positive Phase 2 results for ABCL635 and a US$200 million offering without a significant premium or discount. Analysts, however, consider the stock to be 36% undervalued based on multi-program T cell engager collaborations.
Vertex Pharmaceuticals Director Sangeeta Bhatia Sells 271 Shares at $547.86 Each on November 16, 2026
Vertex Pharmaceuticals Director Sangeeta N. Bhatia sold 271 shares of company common stock at $547.86 per share on November 16, 2026, as revealed in a Form 4 filed with the SEC on November 18, 2026. This transaction was executed under a pre-established Rule 10b5-1 trading plan. Following the sale, Dr. Bhatia directly holds 4,653 shares of Vertex Pharmaceuticals.
After selling 1,000 shares of Vertex Pharmaceuticals (VRTX), Nancy Thornberry directly held 1,109.
Nancy Thornberry, a director of Vertex Pharmaceuticals Inc. (VRTX), sold 1,000 shares of common stock on November 16, 2026, at $547.86 per share under a Rule 10b5-1 trading plan. Following this transaction, she directly held 1,109 shares of the company. The sale was officially filed on November 18, 2026.
At $547.86 apiece, a director sold 271 Vertex Pharmaceuticals (VRTX) shares.
Vertex Pharmaceuticals Inc. (VRTX) director Sangeeta N. Bhatia sold 271 shares of common stock at $547.86 per share on November 16, 2026. This transaction was executed under a Rule 10b5-1 trading plan established on August 13, 2026. Following the sale, Dr. Bhatia directly holds 4,653 shares of the company.
Maze Therapeutics CEO Jason Coloma: MZE829 Could Be the First Real Drug for a Kidney Disease That Hits 1 Million Americans Under 50
Maze Therapeutics CEO Jason Coloma detailed at the Jefferies Global Healthcare Conference how their lead drug, MZE829, could be the first effective treatment for APOL1-mediated kidney disease, affecting 1 million Americans under 50. MZE829 employs a dual mechanism to block and prevent the reformation of toxic pores in kidney cells, distinguishing it from competitors like Vertex. The company anticipates full Phase 2 HORIZON trial data in early 2027, targeting at least a 30% reduction in urine protein.
Genomics extends drug discovery collaboration with Vertex
Genomics, a TechBio company, has announced a four-year extension of its drug target discovery and validation collaboration with Vertex Pharmaceuticals. This extension builds on an eight-year partnership, focusing on using human genetics to discover and validate drug targets and biomarkers for precision medicines. The collaboration aims to advance the understanding of human genetic variation in diseases with significant unmet needs, with a potential contract value exceeding $220 million.
Vertex signs $220M deal with Genomics to re-up long-running discovery pact
Vertex Pharmaceuticals has extended its partnership with sequencing specialist Genomics, signing a new four-year deal worth up to $220 million. This re-ups an existing eight-year collaboration, focusing on leveraging Genomics' discovery platform and extensive human genotype-phenotype database for identifying new disease targets. The agreement, subject to various milestones and potential royalties, continues Vertex's strategy of incorporating human genetics into its research and development of therapies.
Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals
Genomics Ltd. announced a four-year extension of its strategic drug target discovery and validation collaboration with Vertex Pharmaceuticals, building on an existing eight-year partnership. This collaboration focuses on leveraging human genetics for novel drug target and biomarker identification, aiming to develop precision medicines for diseases with significant unmet needs. The extended agreement has a potential contract value exceeding $220 million, tied to research, development, regulatory, and commercial milestones, plus tiered royalties on future net sales.
Sickle Cell Drug: Marrow Raises $173 Million Without Releasing Anemia or Selectivity Data
Marrow Therapeutics launched with $173 million in Series A and B financing to develop MAR-101, a sickle cell and beta thalassemia drug that targets the fetal hemoglobin repressor BCL11A. The drug, which has not yet been tested in humans, aims to be an alternative to gene therapy but lacks public data on its ability to spare red cells' iron supply and selectively silence BCL11A. Investors include OrbiMed, Scion Life Sciences, and venBio, funding manufacturing efforts for global access.
VRTX: Pivotal renal readouts and expanding non-CF revenue shape the 2027 outlook
Vertex Pharmaceuticals (VRTX) anticipates key catalysts in 2027, including pivotal renal readouts with AMPLITUDE interim data in Q1 and additional kidney and pain study results throughout midyear. A decision for povetacicept’s IgAN is expected on November 30, 2026, and the company projects further growth in its non-CF revenue for 2027. This outlook is based on insights from the Jefferies Global Healthcare Conference audio transcript on November 17, 2026.
Natera Short Interest Rises As Bets Remain Near September Peak
Natera Inc. (NASDAQ:NTRA) saw its short interest rise by 3.77% to 6.07 million shares as of October 30, 2026, representing 4.31% of the float. This level is just below the September 30 peak of 6.36 million shares. The company's shares were down 3.22% at $279.18 on Tuesday, significantly below its 52-week high.
CRISPR Therapeutics CEO Sam Kulkarni says investors are "sleeping on gene editing" as one-shot therapy takes on siRNA
CRISPR Therapeutics CEO Sam Kulkarni argues that gene editing is transitioning from a scientific endeavor to a commercial product, with Casgevy generating significant revenue and a pipeline of promising assets. Kulkarni asserts that gene editing's one-and-done approach will ultimately outperform chronic dosing economically, even as the company diversifies into siRNA assets to generate short-term catalysts. He highlights the mechanistic and health-economic advantages of gene editing, suggesting that payers may prefer upfront costs over decades of chronic treatment.
Should You Invest in the VanEck Biotech ETF (BBH)?
The VanEck Biotech ETF (BBH), launched in December 2011, is a passively managed ETF offering broad exposure to the Healthcare - Biotech segment. With an expense ratio of 0.35% and $521.91 million in assets, it has returned 31.47% year-to-date. BBH holds a Zacks ETF Rank of 2 (Buy) and is considered a high-risk option due to its concentrated holdings.
Pharvaris N.V. Ransomware Attack by N0n
Pharvaris N.V., a healthcare company based in the Netherlands, has been subjected to a ransomware attack by the n0n threat group. The attack was discovered on November 16, 2026, and the n0n group has claimed responsibility. This incident is part of a broader campaign by n0n, which has targeted 205 victims across various sectors, including healthcare, since September 2026.
Director Nancy A. Thornberry proposes selling 1,000 Vertex Pharmaceuticals (VRTX) shares.
Nancy A. Thornberry, a director at Vertex Pharmaceuticals (VRTX), has proposed selling 1,000 common shares with an aggregate market value of $547,860.00. The proposed sale is scheduled for approximately November 16, 2026, and the shares were acquired through restricted-stock vesting in 2024 and 2025. This transaction is being conducted under Rule 10b5-1, allowing insiders to plan trades in advance.
Verastem, Inc. Ransomware Attack by N0n
Verastem, Inc., a biopharmaceutical company, has been identified as a victim of a ransomware attack by the "n0n" group. The attack was discovered on November 16, 2026, with a 100% confidence level and medium severity. The n0n group, which has been active since September 2026, has claimed 203 victims to date and frequently targets the healthcare industry.
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 16 November By Investing.com
This article announces the filing of Form 144 for VERTEX PHARMACEUTICALS INC / MA on November 16, 2026. The filing indicates an intent to sell restricted securities. The brief notice highlights the company's stock symbol VRTX and mentions its current positive performance.
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 16 November By Investing.com
This article announces the filing of Form 144 for VERTEX PHARMACEUTICALS INC / MA, dated November 16. Form 144 is a notice of the intent to sell restricted securities. The article provides this information as a direct announcement without further details or analysis.
Director Sangeeta N. Bhatia proposes selling 271 Vertex Pharmaceuticals (VRTX) shares.
Sangeeta N. Bhatia, a director at Vertex Pharmaceuticals Inc. (VRTX), has filed a notice to sell 271 common shares, valued at approximately $148,470.06, with a proposed sale date of November 16, 2026. The shares were acquired through restricted stock vesting on May 1, 2025, and the filing indicates an August 13, 2026 date for a Rule 10b5-1 plan adoption.
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
Vertex Pharmaceuticals is nearing a crucial Nov. 30 FDA decision for its kidney disease treatment, povetacicept, for IgAN, and executives anticipate a successful launch if approved. The company is also expecting significant revenue contributions from its non-cystic fibrosis products, JOURNAVX and CASGEVY, and has several other pipeline readouts on the horizon, including phase 3 data for inaxaplin in AMKD and JOURNAVX in diabetic peripheral neuropathy. Despite some investor concerns about manufacturing and reimbursement, Vertex remains optimistic about its diverse pipeline and market opportunities in kidney disease and pain management.
VRTX: IgAN launch readiness and a packed 2027 kidney, pain and CAH catalyst calendar
Vertex Pharmaceuticals (VRTX) is experiencing balanced third-quarter growth, with JOURNAVX and CASGEVY projected to exceed $500 million in contributions by 2026. Upcoming catalysts include a povetacicept decision by November 30, 2026, as well as new data for kidney and pain treatments and Phase III results for Congenital Adrenal Hyperplasia (CAH) expected in late 2027 or early 2028. This outlook is based on insights from the UBS Global Biopharma Conference 2026.
Biohaven (BHVN) Could Be 67% Undervalued After Graves Data And Ono Deal
Biohaven (BHVN) is gaining attention after presenting new Graves' disease data and announcing an international licensing deal with Ono Pharmaceutical. Despite recent mixed trading, analysts suggest the company could be 67% undervalued, with a fair value of $42.29, driven by optimistic trial outcomes for BHV-1300 and the potential for new revenue streams. However, ongoing cash burn and potential dilution are noted risks.
Evotec kommt kaum vom Fleck: Jetzt entscheidet dieser Faktor
The Evotec stock is currently stagnant, closing the week at 2.97 Euro with a 1.8 percent loss, sparking intense debate among investors about its future direction. Discussions center on whether an ongoing restructuring and potential improvements in operating business will lead to a recovery, or if the market is overestimating the impact of the current share buyback program, which is primarily intended for employee stock plans rather than reducing the overall share count. The stock's future hinges on tangible operational news and increased trading volume to support any recovery from its current low.
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 14 November By Investing.com
This article announces the filing of Form 144 for Vertex Pharmaceuticals Inc. (VRTX) on November 14, 2026. Form 144 is a notice of the intent to sell restricted securities. The article includes current financial market data, including various indices, commodities, and bond yields, and lists trending and most popular articles related to market analysis and specific stocks.
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 14 November By Investing.com
This article announces the filing of Form 144 for Vertex Pharmaceuticals Inc. (VRTX) on November 14. The document pertains to insider transactions and is a standard regulatory disclosure for sales of restricted stock. The piece provides the raw announcement without further elaboration on the details of the filing or its implications.
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 14 November By Investing.com
This article announces the filing of Form 144 for VERTEX PHARMACEUTICALS INC / MA on November 14. The brief report highlights the company's stock symbol (VRTX) and its current performance (-0.74%). The content is a standard financial news brief from Investing.com, providing basic information about the SEC filing.
Two Medical Giants Diverge in Strategy as Investors Face a Choice Between Steady Returns and High Growth
Amgen (AMGN) and Vertex Pharmaceuticals (VRTX) offer investors distinct choices: Amgen provides steady returns with a lower valuation, strong cash flow, and diversified operations, appealing to those seeking stability. Vertex, while growing faster with conservative finances and a promising pipeline, comes with a higher valuation and concentrated revenue. Investors must weigh these differences based on their individual risk and return preferences.
Digital Health in Chronic Disease: What's Working, What's Scaled, and What's Next
This article announces an HLTH Insider event sponsored by Vertex Pharmaceuticals, focusing on the current state and future of digital health in chronic disease management. The event aims to bring together executives from Pharma and Healthtech to discuss successful digital tools, the challenges of scaling them beyond point solutions, and how to foster effective partnerships to improve patient outcomes. The discussion will cover what's working, what's scaled, and what's next in this critical area of healthcare.
Anthropic CEO's AI disease cure timeline faces pharma industry pushback
Anthropic CEO Dario Amodei's prediction that AI will cure major diseases within 10 years has met with strong skepticism from pharmaceutical industry leaders. Executives from Eli Lilly and Vertex Pharmaceuticals dispute the feasibility, citing the slow pace of clinical trials, data scarcity, and the 14-year average for FDA drug approval. This disconnect between AI optimism and regulatory reality highlights significant challenges for rapid drug discovery and approval.
A passive holder reports sole voting power over 17.8M Vertex Pharmaceuticals (VRTX) shares.
Capital Research Global Investors has reported beneficial ownership of 17,821,661 common shares, or 7.0%, of Vertex Pharmaceuticals Inc. (VRTX) as of September 30, 2026. This Schedule 13G/A filing indicates that the firm holds sole voting power over 17,794,137 shares and sole dispositive power over all 17,821,661 shares. The report specifies that shared voting and dispositive powers were both zero.
Immunic Inc (IMUX) Stock Price, Quote, News & History
This Benzinga article provides a comprehensive overview of Immunic Inc (IMUX) stock, including its current price, news, key data, and analyst ratings. As of November 13, 2026, IMUX was trading at $7.52, with recent news highlighting the appointment of Erik Lundgren as CEO and a new Medical Officer. The company is a clinical-stage biopharmaceutical firm focusing on oral immunology therapies for chronic inflammatory and autoimmune diseases.
Vertex Pharmaceuticals stock: FDA decision sets next catalyst
Vertex Pharmaceuticals (VRTX) is awaiting a crucial FDA decision on povetacicept for IgA nephropathy, scheduled for November 30. This decision could significantly expand the company's commercial portfolio beyond cystic fibrosis. Additionally, investors are looking to early 2027 for interim AMPLITUDE trial results for inaxaplin and monitoring the JOURNAVX patient support program for its nonopioid pain medicine.
Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly outperformed the market over the last decade, with an annualized return of 19.42%. An investment of $1000 in VRTX stock ten years ago would now be worth $5,947.94, highlighting the substantial impact of compounded returns. The company currently holds a market capitalization of $137.57 billion.
IONS vs VRTX stock comparison - side by side
This article provides a side-by-side comparison of Ionis Pharmaceuticals Inc. (IONS) and Vertex Pharmaceuticals Incorporated (VRTX), both operating in the Biotechnology: Pharmaceutical Preparations sector. VRTX, with a significantly larger market cap, has outperformed IONS over the past year. The comparison highlights their market capitalization, price performance, sector, recent news activity, and analyst ratings, along with detailed company descriptions and recent news updates for each.
What Tecogen (TGEN) Said on Its Q3 Earnings Call
Tecogen (TGEN) reported improved third-quarter financial results, with a 9.6% increase in revenue to $7.9 million and a narrowed net loss of $1.6 million, primarily driven by better performance in its service business. The company also unveiled a new modular dual-power package designed for data centers and other large facilities, which aims to address power needs, offer dynamic switching between electricity and natural gas, and provide higher margins. Tecogen's product backlog exceeded $8 million, and it is actively pursuing initial deployments and pilot sites for its new modular solution.
MediWound's Penny EPS Beat Is Overshadowed By A 53% Revenue Miss And A Retreat From Its 2026 Revenue Outlook
MediWound technically beat EPS estimates but missed revenue consensus by 53.2% and retracted its 2026 revenue outlook due to unpredictable U.S. government funding. While the company saw improvements in gross margin, NexoBrid demand, and government contracts, its near-term financial stability is compromised, and the balance sheet required fresh equity. Investors are now focused on the mid-2027 VALUE clinical trial readout and capacity expansion rather than immediate revenue figures.
Vertex Pharma stock rises as FDA decision nears
Vertex Pharmaceuticals (VRTX) stock is rising as the FDA's November 30 decision date for povetacicept in IgA nephropathy approaches. The company recently raised its full-year 2026 revenue guidance following strong third-quarter results, indicating growth beyond its core cystic fibrosis products. Despite increased acquisition and commercialization costs impacting GAAP earnings, the raised outlook and potential FDA approval for a new nephrology franchise are broadening Vertex's investment appeal.
An officer's proposed sale covers 15,286 Vertex Pharmaceuticals (VRTX) shares.
Charles F. Wagner Jr., an officer at Vertex Pharmaceuticals Inc. (VRTX), has proposed selling 15,286 common shares, valued at approximately $8.37 million, with an anticipated sale date of November 12, 2026. The shares were acquired through ESPP purchases and restricted stock vesting between November 2023 and May 2025. This proposed sale was filed with the SEC as a Form 144, indicating a neutral impact and sentiment.
A €680M tax benefit helps turn loss to profit at Ascendis Pharma (ASND).
Ascendis Pharma A/S reported a significant nine-month net profit of €910.283 million for 2026, a substantial turnaround from a €194.472 million loss in 2025. This profit was largely driven by a €679.587 million tax benefit from the recognition of previously unrecognized deferred tax assets and €158.067 million from the sale of a priority review voucher. The company also saw increased revenue from its commercial products, YORVIPATH, SKYTROFA, and the newly launched YUVIWEL.
A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
Five biotech companies—BridgeBio, Vertex, Gilead, Viatris, and Praxis—have FDA target action dates between November 27 and December 27, 2026. These PDUFA dates mark when pending applications could be decided, with Vertex's povetacicept for IgA nephropathy on November 30 being a key highlight. The report also details Q3 revenues and 2026 guidance for several companies, noting positive updates for Vertex, Gilead, and Viatris, alongside flat Q3 revenues for Viatris.
A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
The final weeks of 2026 are marked by a cluster of U.S. Food and Drug Administration (FDA) target action dates for several drugmakers. Five companies, including BridgeBio Pharma, Vertex Pharmaceuticals, Gilead Sciences, Viatris Inc., and Praxis Precision Medicines, have Prescription Drug User Fee Act (PDUFA) dates between November 27 and December 27, 2026, covering a range of applications for conditions such as muscular dystrophy, IgA nephropathy, multiple myeloma, acute pain, and epileptic encephalopathies. These dates are crucial milestones for the companies and their investigational drugs, though they do not guarantee FDA approval.
Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research
Unlearn and Structure Therapeutics announced a collaboration to explore the application of AI-generated "digital twins" in obesity research. This retrospective analysis will use AI-based modeling to estimate what patient outcomes might have been without investigational treatment, providing additional context for longer-term obesity study results. The findings will be presented at ObesityWeek 2026.
Data Center Cooling Market to Reach US$ 42 Bn by 2031, Growing at 16.5% CAGR as AI Racks Push Cooling From Air to Liquid: Wissen Research
The global data center cooling market is projected to reach USD 42 billion by 2031, growing at a CAGR of 16.5%, driven by the increasing demand for AI and high-performance computing workloads. While air-based cooling currently dominates due to existing infrastructure, there's a significant shift towards more efficient liquid cooling solutions to manage higher thermal loads and meet growing sustainability regulations. Key players are focusing on innovation in liquid cooling, energy efficiency, and integrated thermal management systems to address these evolving market demands.
A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
The biotech industry is facing a busy end to 2026, with several U.S. FDA target action dates scheduled from late November to late December. Five companies—BridgeBio Pharma, Vertex Pharmaceuticals, Gilead Sciences, Viatris Inc., and Praxis Precision Medicines—have Prescription Drug User Fee Act (PDUFA) dates for various drug applications covering conditions like muscular dystrophy, IgA nephropathy, multiple myeloma, acute pain, and epileptic encephalopathies. These dates are crucial for the companies as they await regulatory decisions that could significantly impact their product pipelines and market performance.
Vertex Pharma stock heads toward pivotal FDA decision
Vertex Pharmaceuticals is nearing a significant FDA decision on November 30 for povetacicept, a potential new therapy for IgA nephropathy, which could establish nephrology as a new commercial franchise. The company reported strong third-quarter sales with a 12 percent year-over-year revenue increase, leading to an upward revision of its full-year 2026 revenue guidance to between 13.15 billion and 13.25 billion US dollars, despite a decrease in GAAP net income due to acquisition costs. Investors are closely watching both this regulatory catalyst and the performance of new products like Casgevy, Journavx, and Palsonify as the company diversifies beyond its dominant cystic fibrosis franchise.
What Will Decide Vertex Stock Over The Next Six Months?
Vertex Pharmaceuticals (VRTX) stock has outperformed the S&P 500 over the past year and faces several key events in the next six months that could significantly impact its share price. These include an FDA decision on povetacicept for IgA nephropathy, interim results for inaxaplin, its fiscal Q4 2026 earnings report, and proof-of-concept data for povetacicept in generalized myasthenia gravis. The company is also managing its patient support program for JOURNAVX, which affects the drug's net revenue.